Top Clinical Trials companies in Australia by Receivables

This ranking features the top 10 Clinical Trials companies in Australia ranked by Receivables, totaling a Receivables of USD 2.83 B, for February 06, 2025.
#
Name
Receivables
Reported Date
Stock Price
Change
Price (30 days) Country
1
USD 2.64 B
June 30, 2024 USD 169.95 -0.56%

Australia

2
USD 54.30 M
June 30, 2024 USD 2.33 0.08%

Australia

3
USD 44.11 M
Dec. 31, 2023 USD 18.33 -0.84%

Australia

4
USD 20.95 M
June 30, 2024 USD 1.90 -4.74%

Australia

5
USD 20.40 M
June 30, 2024 USD 0.74 0.62%

Australia

6
USD 17.49 M
June 30, 2024 USD 7.27 0.71%

Australia

7
USD 13.82 M
June 30, 2024 USD 1.23 -0.40%

Australia

8
USD 9.96 M
June 30, 2024 USD 0.74 1.48%

Australia

9
USD 5.04 M
June 30, 2024 USD 2.09 0.97%

Australia

10
USD 865.07 K
Dec. 31, 2023 USD 6.16 2.82%

Australia

Frequently Asked Questions
  • Which Clinical Trials company in Australia has the highest Receivables ?

    The Clinical Trials company in Australia with the highest Receivables is CSL Limited (ASX: CSL.AX) at USD 2.64 B.

  • Which Clinical Trials company in Australia has the lowest Receivables ?

    The Clinical Trials company in Australia with the lowest Receivables is Anteris Technologies Ltd (ASX: AVR.AX) at USD 865.07 K.

SV Wall Street